Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular analysis-directed individualized therapy versus standard cisplatin-based chemotherapy in advanced non-small-cell lung cancer
ChiCTR-TRC-11001327Phase 4Completed
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisplatin, vinorelbine, gemcitabine, paclitaxel, etoposide and 1 more in non-small cell lung cancer (NSCLC) (6 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Progression-free survival. Started Oct 2010; status: completed.
02
Drugs
cisplatinvinorelbinegemcitabinepaclitaxeletoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001327.